NASDAQ$ALLO
Allogene Therapeutics Inc. · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Allogene Therapeutics reported Q4 2024 a net loss of $59.9M, diluted EPS of $-0.28.
For Q4 2024, Allogene Therapeutics reported net loss was $59.9M, diluted EPS was $-0.28. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $59.9M.
- Diluted EPS $-0.28.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Allogene · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and trial outcomes affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+1.1%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-5.0%
Avg return
30 days after
53%
16 / 30 earnings
Positive
+23.7%
Q3 2023
Best reaction
-11.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -16.0% | -17.7% | |
| Q4 2025 | -2.8% | -13.0% | +10.1% | |
| Q3 2025 | +10.7% | +17.1% | +36.2% | |
| Q1 2025 | -1.8% | -1.8% | +23.4% | |
| Q4 2024 | +2.6% | -10.6% | -23.3% | |
| Q3 2024 | -4.3% | -11.8% | -32.0% | |
| Q2 2024 | -7.5% | -7.5% | -5.5% | |
| Q1 2024 | +7.2% | +0.4% | -6.9% | |
| Q4 2023 | -4.5% | -10.0% | -22.1% | |
| Q3 2023 | +23.7% | +15.9% | -11.0% | |
| Q2 2023 | +7.3% | -11.3% | -15.4% | |
| Q1 2023 | +20.6% | +18.1% | +4.9% | |
| Q4 2022 | +0.2% | -5.4% | -21.5% | |
| Q3 2022 | -9.9% | -14.2% | -10.5% | |
| Q2 2022 | +1.5% | +8.1% | -3.5% | |
| Q1 2022 | +2.3% | -18.9% | -8.0% | |
| Q4 2021 | -4.8% | -5.9% | -0.7% | |
| Q3 2021 | -0.1% | -5.8% | -12.6% | |
| Q2 2021 | +8.2% | +3.2% | +16.1% | |
| Q1 2021 | -0.7% | -1.4% | -19.0% | |
| Q4 2020 | +0.8% | +0.5% | -1.9% | |
| Q3 2020 | -11.8% | -17.5% | -0.4% | |
| Q2 2020 | +0.3% | -0.6% | -10.9% | |
| Q1 2020 | -0.9% | +8.2% | +38.1% | |
| Q4 2019 | +6.1% | +8.1% | -21.7% | |
| Q3 2019 | -10.5% | -5.5% | +2.1% | |
| Q2 2019 | +4.4% | -0.9% | -7.4% | |
| Q1 2019 | -2.1% | -2.5% | -16.5% | |
| Q4 2018 | -4.7% | -9.3% | -5.7% | |
| Q3 2018 | +3.8% | +8.3% | -5.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro